Results 11 to 20 of about 43,976 (245)

Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery

open access: yesFrontiers in Pharmacology, 2021
Anticancer chemotherapies have been shown to produce severe side effects, with cardiotoxicity from anthracycline being the most notable. Identifying risk factors for anticancer therapy-induced cardiotoxicity in cancer patients as well as understanding ...
Wendy Keung   +2 more
doaj   +1 more source

Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity

open access: yesFrontiers in Pharmacology, 2023
Background: Doxorubicin-induced cardiotoxicity represents a prevalent adverse effect encountered in patients undergoing treatment with doxorubicin. To date, there has been no bibliometric study to summarize the field of doxorubicin-induced cardiotoxicity.
Xiaoxiao Lin   +3 more
doaj   +1 more source

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters

open access: yesESC Heart Failure, 2022
Aims To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation. Methods and results Seventy‐two women with breast cancer (52 ± 
Belén Díaz‐Antón   +14 more
doaj   +1 more source

Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies

open access: yesDiagnostics, 2023
Improvements in the treatment of childhood cancer have considerably enhanced survival rates over the last decades to over 80% as of today. However, this great achievement has been accompanied by the occurrence of several early and long-term treatment ...
Kondylia Antoniadi   +6 more
doaj   +1 more source

Nrf2: a dark horse in doxorubicin-induced cardiotoxicity

open access: yesCell Death Discovery, 2023
Being a broad-spectrum anticancer drug, doxorubicin is indispensable for clinical treatment. Unexpectedly, its cardiotoxic side effects have proven to be a formidable obstacle.
Xiaopeng Zhao   +3 more
doaj   +1 more source

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis

open access: yesFrontiers in Immunology, 2022
Immune checkpoint inhibitors (ICIs) in combination withother anti-cancer treatments have been approved for a variety of cancers. While the difference in the incidence of cardiovascular adverse events has not been fully investigated.
Maobai Liu   +11 more
doaj   +1 more source

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

open access: yesFrontiers in Oncology
ObjectiveTo investigate the risk factors associated with cardiotoxicity in patients with non-small cell lung cancer (NSCLC) treated with osimertinib.MethodsA total of 268 patients with NSCLC treated with osimertinib in our hospital from June 2019 to ...
Yunlong Wang   +3 more
doaj   +1 more source

Risk Compounds, Preclinical Toxicity Evaluation, and Potential Mechanisms of Chinese Materia Medica–Induced Cardiotoxicity

open access: yesFrontiers in Pharmacology, 2021
Chinese materia medica (CMM) has been applied for the prevention and treatment of diseases for thousands of years. However, arrhythmia, myocardial ischemia, heart failure, and other cardiac adverse reactions during CMM application were gradually reported.
Jie Zhou   +14 more
doaj   +1 more source

Particulate matter induces arrhythmia-like cardiotoxicity in zebrafish embryos by altering the expression levels of cardiac development- and ion channel-related genes

open access: yesEcotoxicology and Environmental Safety, 2023
Air pollution is a risk factor that increases cardiovascular morbidity and mortality. In this study, we investigated the cardiotoxicity of particulate matter (PM) exposure using a zebrafish embryo model.
Kyu Hee Park   +8 more
doaj   +1 more source

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

open access: yesActa Oncologica
Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF).
Jonas K. Oddershede   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy